Rosen R C, Seftel A D
New England Research Institutes, Watertown, MA 02472, USA.
Int J Impot Res. 2008 Dec;20 Suppl 3:S27-32. doi: 10.1038/ijir.2008.52.
Erectile dysfunction (ED) and benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) share many epidemiologic and clinical similarities. First-line therapy for both conditions include oral medications (alpha blockers, phosphodiesterase inhibitors). The impetus to develop and use questionnaires to characterize these two conditions is based on the trend away from invasive diagnostic testing to the use of patient-reported outcomes or validated self-administered questionnaires. The International Prostate Symptom Score, the International Index of Erectile Function, the Male Sexual Health Questionnaire (MSHQ) and the MSHQ short form are similar patient-reported assessment questionnaires used for research or clinical evaluation of BPH/LUTS, ED and ejaculatory dysfunction. These patient-based self-administered questionnaires are likely to assume an ever increasing important role in the future, as oral BPH therapies are considered for the treatment of ED and oral ED therapies are considered for the treatment of BPH/LUTS.
勃起功能障碍（ED）与良性前列腺增生/下尿路症状（BPH/LUTS）在流行病学和临床方面有许多相似之处。这两种病症的一线治疗方法都包括口服药物（α受体阻滞剂、磷酸二酯酶抑制剂）。开发和使用问卷来描述这两种病症的动力基于从侵入性诊断测试转向使用患者报告结局或经过验证的自我管理问卷的趋势。国际前列腺症状评分、国际勃起功能指数、男性性健康问卷（MSHQ）及其简表是用于BPH/LUTS、ED和射精功能障碍研究或临床评估的类似患者报告评估问卷。随着口服BPH治疗被考虑用于治疗ED，口服ED治疗被考虑用于治疗BPH/LUTS，这些基于患者的自我管理问卷在未来可能会发挥越来越重要的作用。
